Nyxoah SA(NYXH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 9 at 4:00 PM ET (Korea 10/10 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.52 | Insider Own | 20.18% | Shs Outstand | 100.1M | Perf Week | - |
| Market Cap | 0.14B | Forward P/E | - | EPS next Y | 37.7% | Insider Trans | - | Shs Float | 81.3M | Perf Month | -9.33% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.35 | Inst Own | 23.68% | Short Float | 0.4% | Perf Quarter | -17.07% |
| Income | -0.11B | P/S | 5.49 | EPS this Y | 52.44% | Inst Trans | 16.55% | Short Ratio | 1.17 | Perf Half Y | -52.45% |
| Sales | 0.03B | P/B | 1.43 | EPS next 5Y | 42.94% | ROA | -67.96% | Short Interest | 0.32M | Perf YTD | -70.43% |
| Book/sh | 0.95 | P/C | 1.24 | EPS past 3/5Y | -28.04% -28.17% | ROE | -123.53% | 52W High | -80.22% ($6.87) | Perf Year | -78.72% |
| Cash/sh | 1.1 | P/FCF | - | Sales past 3/5Y | 51.67% 170.1% | ROIC | -81.97% | 52W Low | 7.94% ($1.26) | Perf 3Y | -80.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -9.99% | Gross Margin | 30.34% | Volatility(W/M) | 4.37% 4.99% | Perf 5Y | -94.96% |
| Dividend TTM | - | EV/Sales | 3.77 | Sales Y/Y TTM | 369.67% | Oper. Margin | -393.88% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.29 | EPS Q/Q | -7.74% | Profit Margin | -443.15% | RSI (14) | 44.04 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.37 | Sales Q/Q | 487.55% | SMA20 | -4.86% ($1.43) | Beta | 1.76 | Target Price | $5.37 |
| Payout | - | Debt/Eq | 0.72 | Earnings | 2026/8/5 | SMA50 | -9.62% ($1.5) | Rel Volume | 0.13 | Prev Close | $1.35 |
| Employees | - | LT Debt/Eq | 0.44 | EPS/Sales Surpr. | -48.92% 1.3% | SMA200 | -51.18% ($2.79) | Avg Volume(3M) | 0.28M | Price | $1.36 |
| IPO | 2021/4/28 | Option/Short | No/Yes | Trades | 236 | Volume | 36,133 | Change | 0.74% |
😴 Nyxoah is a Belgium-based medical device company that develops and commercializes implantable neurostimulation systems for the treatment of obstructive sleep apnea. Founded in 2009, the company operates around a small, battery-free, leadless implanted device that is powered externally, and it is expanding its presence in the alternative therapy market aimed at patients who cannot adapt to conventional CPAP treatment.
Over the past 1 year, on the lower side
80% below its 1-year high.
Traded less than usual That is 13% of its average volume.
NYXH has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $549. Peers typically go for $157.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.0%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 23.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SPEU State Street SPDR Portfolio Europe ETF <0.01% It ranks #82 of 143 in the industry
Based on market cap of $139M.
FAQ
What kind of company is NYXH?
NYXH belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NYXH?
The market cap of NYXH is approximately $139M, ranking 4,350 within its sector.
What is the 52-week high and low for NYXH?
NYXH has recorded a 52-week high of $6.87 and a low of $1.26.
